David Michael Johnson Zentalis Pharmaceuticals, Inc. (ZNTL) insider trading activity

David Michael Johnson is Director of Zentalis Pharmaceuticals, Inc.. Currently has a direct ownership of 250,421 shares of ZNTL, which is worth approximately $315,530. The most recent transaction as insider was on Jun 17, 2025, when has been sold 57,603 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 250K

29.87% 3M change

29.87% 12M change

Total Value Held $315,530

David Michael Johnson Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 17 2025	BUY Grant, award, or other acquisition	-	57,603 Added 18.7%	250,421 Common Stock
Jun 21 2024	BUY Grant, award, or other acquisition	-	48,429 Added 20.07%	192,818 Common Stock
Nov 10 2023	BUY Open market or private purchase	$167,960 $9.88 p/Share	17,000 Added 10.53%	144,389 Common Stock
Jun 16 2023	BUY Grant, award, or other acquisition	-	19,059 Added 13.01%	127,389 Common Stock
Jun 08 2022	BUY Grant, award, or other acquisition	-	24,871 Added 18.67%	108,330 Common Stock
Oct 04 2021	SELL Open market or private sale	$858,616 $66.58 p/Share	12,896 Reduced 13.74%	80,959 Common Stock
Jun 04 2021	BUY Grant, award, or other acquisition	-	5,000 Added 5.06%	93,855 Common Stock
Apr 05 2021	SELL Open market or private sale	$561,020 $43.5 p/Share	12,897 Reduced 12.67%	88,855 Common Stock
Dec 02 2020	SELL Open market or private sale	$660,791 $51.24 p/Share	12,896 Reduced 11.25%	101,752 Common Stock
Apr 07 2020	BUY Open market or private purchase	$72,000 $18.0 p/Share	4,000 Added 3.37%	114,648 Common Stock

Also insider at

AURA

Aura Biosciences, Inc. Healthcare

DMJ